Drug developers
Turn access risk into parallel workstreams before authorization.
Road to Access resources
Working resourceDelivery
Psychedelic Therapy Launch-Readiness Checklist
A practical Road to Access checklist for turning a positive clinical and regulatory path into reimbursed, governed, and deliverable psychedelic-assisted therapy.
- Checklist lanes
- 8
- Core risk
- Timing
- Public status
- Working
Evidence, HTA, payment, sites, workforce, data, governance, equity
Access work must start before approval
Scenario tool, not medical or reimbursement advice
At a glance
What to take from this page
- Launch readiness is a system capability, not just a regulatory milestone.
- Evidence, payment, workforce, and site governance need to mature in parallel.
- The checklist is designed to expose missing workstreams early.
Who this helps
Operators
Translate a protocol into sites, people, rooms, data, and governance.
Investors and policy readers
Assess whether the ecosystem is ready for real access rather than only approval.
Launch readiness
Approval is only one lane in the launch system
Each lane needs an owner, a source-backed assumption set, and a concrete path into routine care before a positive decision can become patient access.
Evidence
1Clinical / HEOR
Endpoint, comparator, durability, safety, resource use
HTA
2Market access
Model, uncertainty plan, patient selection, value story
Payment
3Payer / provider
Drug, service, monitoring, registry, and site-cost object
Sites
4Operations
Rooms, pharmacy, escalation, referral, contracting
Workforce
5Clinical governance
Training, supervision, protected time, medical cover
Data
6Evidence operations
Baseline, follow-up, relapse, retreatment, adverse events
Governance
7Provider leadership
Protocol, consent, audit, quality assurance, accountability
Equity
8Payer / policy
Eligibility, geography, wait lists, private spillover
Launch-readiness lanes
| Lane | Question to answer | Evidence of readiness |
|---|---|---|
| Evidence | Do pivotal and follow-up data answer regulator and payer questions? | Endpoints, durability, safety, comparator, and subgroup logic |
| HTA | Can the value case survive national assessment? | Economic model, uncertainty plan, appropriate-use criteria |
| Payment | What exactly is reimbursed? | Drug, preparation, dosing, monitoring, integration, registry, and outcome tracking |
| Sites | Where can care actually happen? | Certified rooms, referral routes, pharmacy, emergency protocols |
| Workforce | Who can safely deliver the pathway? | Training, supervision, availability, medical cover, fidelity |
| Data | How will outcomes and safety be tracked after launch? | Registry, relapse, retreatment, adverse events, resource use |
| Governance | Who is accountable? | Clinical protocols, consent, escalation, audit, quality assurance |
| Equity | Who is excluded by design or cost? | Eligibility, geography, private-payment spillover, waiting-list impact |
How to read the checklist
This checklist is a resource for spotting gaps. It is not a claim that any product, country, or provider is ready today.
The practical question is whether each lane has an owner, source-backed assumptions, and a pathway from evidence to routine delivery.